Treatment of Central Serous Chorioretinopathy When Observation and Risk Factor Management Fail to Resolve Subretinal Fluid

Central serous chorioretinopathy (CSC) is initially managed conservatively. When the first-line approach does not achieve spontaneous resolution of subretinal fluid, a structured next-line intervention is indicated.

First-line approach — goal not reached

Previous treatment

The initial strategy — avoidance of modifiable risk factors (primarily cessation or avoidance of corticosteroids), management of systemic hypertension, psychological stress, obstructive sleep apnoea and Helicobacter pylori infection, and cessation of phosphodiesterase-6 inhibitors — combined with an observation period of 3–4 months, aimed for spontaneous resolution of subretinal fluid within 3–6 months. When this outcome is not achieved, escalation to the next treatment line is warranted.

Next-line treatment approach (partial summary)

The evidence-based next step involves a photodynamic intervention targeting the affected area. An alternative laser-based modality exists for settings where the primary approach is not available. Full protocol parameters, eligibility criteria, and the stepwise algorithm are available via the link below.

Treatment goal

Complete resolution of subretinal fluid at 3-month follow-up.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ceo.14201
Photodynamic therapy (PDT) consists of the intravenous administration of a photosensitising agent, verteporfin, which collects in choroidal blood vessels, followed by targeted application of laser to areas requiring treatment causing excitation of the verteporfin molecules.
The authors concluded that micropulse laser may be of use in treatment of chronic CSC when PDT is not available.
At 3-month follow up, 78% of patients in the half-dose PDT group had complete resolution of SRF versus 17% in the eplerenone group (p < 0.001).

View source ↗